Most Read

Under the terms of the agreement, Shield will receive an immediate £11 million upfront payment, is eligible to receive up to €4.5m in short-term development milestones and up

Bonti is focused on developing fast-acting neurotoxin programs intended to be used in aesthetic and therapeutic applications. According to the acquisition terms, the Irish drug maker will make

Lumoxiti, which is a CD22-directed cytotoxin, has been approved for the patients who had two or prior systemic therapies, including treatment with a purine nucleoside analog. AstraZeneca executive

VEYVONDI should not be used in the treatment of hemophilia A. VEYVONDI is the first and only recombinant von Willebrand Factor (rVWF) treatment in the EU for von Willebrand disease (VWD)

The trial, dubbed IM011-011, enrolled 267 patients to assess the efficacy and safety of BMS-986165 in comparison to placebo. It delivered significant skin clearance, said the US pharma

The Finch 2 is a global, 24-week randomized, double-blind, placebo-controlled and phase 3 study of filgotinib in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response/intolerance to

The FDA has approved new dosage strength (16mg / 4mg) of Cassipa (buprenorphine and naloxone) sublingual film. It is also approved in both brand name and generic versions,

The British pharma giant is seeking approval for mepolizumab as an add-on treatment to inhaled corticosteroid-based maintenance treatment for reducing exacerbations in patients with COPD guided by blood

In this regard, the two firms have signed a global clinical collaboration agreement to assess the safety, tolerability and preliminary efficacy of their drugs combination. Lifirafenib is a